Teva Pharmaceutical Industries Limited (TEVA) Rating Reiterated by Jefferies Group LLC

Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating reiterated by analysts at Jefferies Group LLC in a research report issued on Wednesday, August 9th. They presently have a $26.00 price target on the stock, down from their previous price target of $33.00. Jefferies Group LLC’s price objective would indicate a potential upside of 50.29% from the stock’s current price.

Other analysts have also recently issued reports about the company. Vetr upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $33.12 price target on the stock in a research report on Tuesday, May 2nd. Deutsche Bank AG lowered their price target on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 12th. Citigroup Inc. lowered their price target on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, April 25th. Credit Suisse Group reiterated a “buy” rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, May 17th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, May 31st. Three analysts have rated the stock with a sell rating, twenty have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited currently has an average rating of “Hold” and an average price target of $36.73.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 1.17% during midday trading on Wednesday, reaching $17.30. The company’s stock had a trading volume of 9,162,890 shares. The firm’s market capitalization is $17.58 billion. Teva Pharmaceutical Industries Limited has a 1-year low of $16.81 and a 1-year high of $53.96. The firm has a 50 day moving average price of $27.46 and a 200 day moving average price of $30.98.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter last year, the company earned $1.25 earnings per share. The business’s revenue was up 12.9% on a year-over-year basis. On average, analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Rating Reiterated by Jefferies Group LLC” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2017/08/19/teva-pharmaceutical-industries-limited-teva-earns-hold-rating-from-jefferies-group-llc-updated.html.

Large investors have recently added to or reduced their stakes in the stock. Greylin Investment Mangement Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 36.9% in the second quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock valued at $9,783,000 after buying an additional 79,300 shares during the period. PGGM Investments increased its stake in shares of Teva Pharmaceutical Industries Limited by 12.0% in the second quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock valued at $50,763,000 after buying an additional 163,292 shares during the period. Schulhoff & Co. Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock valued at $372,000 after buying an additional 1,004 shares during the period. Heritage Investors Management Corp increased its stake in shares of Teva Pharmaceutical Industries Limited by 17.5% in the first quarter. Heritage Investors Management Corp now owns 188,990 shares of the company’s stock valued at $6,065,000 after buying an additional 28,135 shares during the period. Finally, Bank Hapoalim BM increased its stake in shares of Teva Pharmaceutical Industries Limited by 9.2% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock valued at $375,000 after buying an additional 980 shares during the period. Institutional investors and hedge funds own 56.04% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit